ArticleNature communications2018
Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 146 citations in OpenAlex.
- A RANKLBone research · 2026Article
- Cell signaling and transcriptional regulation of osteoclast lineage commitment, differentiation, bone resorption and diseases.Cell discovery · 2026Review
- Fluid shear stress activates c-Src and promotes RANKL localization in the plasma membrane in osteoblast-like MC3T3-E1 cells.BBA advances · 2026Article
- Inhibition of membrane RANKL production in osteoblasts mediates curcumin-inhibited osteoclastogenesis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Antcin K suppresses osteoclastogenesis through modulation of the focal adhesion kinase and phosphoinositide 3-kinase pathways and attenuates ligature-induced periodontitis.Journal of dental sciences · 2026Article
- Crosstalk between endothelial cells and osteoblasts stimulates ALP via Notch signaling and RANKL/OPG ratio independently of Notch signaling in vitro.Cellular & molecular biology letters · 2025Article
- Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The p53-miR17 family-Rankl axis bridges liver-bone communication.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Osteocytes function as biomechanical signaling hubs bridging mechanical stress sensing and systemic adaptation.Frontiers in physiology · 2025Review
- Polymorphisms in rs2069845 are associated with IL-6 and soluble IL-6 receptor levels during total joint replacement.PloS one · 2025Article
- Ugonin P mitigates osteolytic bone metastasis by suppressing MDK via upregulating miR-223-3p expression.International journal of biological sciences · 2025Article
- Metabolic reprogramming in skeletal cell differentiation.Bone research · 2024Review
- Article
- RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.International journal of molecular sciences · 2024Review
- Bone Regenerative Effect of Injectable Hypoxia Preconditioned Serum-Fibrin (HPS-F) in an Ex Vivo Bone Defect Model.International journal of molecular sciences · 2024Article
- Article
- Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss.Cell communication and signaling : CCS · 2024Article
- Ferroptosis in Osteocytes as a Target for Protection Against Postmenopausal Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females.Frontiers in endocrinology · 2024Article
- Oral microbiota-host interaction: the chief culprit of alveolar bone resorption.Frontiers in immunology · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Receptor activator of NFkB ligand (RANKL) is a TNF-family cytokine required for osteoclast formation, as well as immune cell and mammary gland development. It is produced as a membrane-bound protein that can be shed to form a soluble protein. We created mice harboring a sheddase-resistant form of RANKL, in which soluble RANKL is undetectable in the circulation. Lack of soluble RANKL does not affect bone mass or structure in growing mice but reduces osteoclast number and increases cancellous bone mass in adult mice. Nonetheless, the bone loss caused by estrogen deficiency is unaffected by the lack of soluble RANKL. Lymphocyte number, lymph node development, and mammary gland development are also unaffected by the absence of soluble RANKL. These results demonstrate that the membrane-bound form of RANKL is sufficient for most functions of this protein but that the soluble form does contribute to physiological bone remodeling in adult mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.